Head and Neck Cancer Archives - Page 21 of 21 - MPR

Head and Neck Cancer

ERBITUX (cetuximab) 2mg/mL injection for intravenous infusion by Bristol-Myers Squibb and Lilly

Erbitux Approved for KRAS-Negative Metastatic Colorectal Cancer

Bristol-Myers Squibb announced that Erbitux (cetuximab), in combination with the chemotherapy regimen FOLFIRI (irinotecan, 5-fluorouracil, leucovorin), has been approved as first-line treatment in KRAS mutation-negative, epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer (mCRC).

AACR: IL-2, 13-Cis Retinoic Acid Beneficial in Advanced Cancer

For patients with advanced cancer, a combination of low-dose interleukin-2 (IL-2) and 13-cis retinoic acid (RA) increases natural killer (NK) cells, decreases expression of vascular endothelial growth factor (VEGF), and improves overall survival (OS).

Cancer Prevention Guidelines Updated

The American Cancer Society (ACS) Nutrition and Physical Activity Guidelines were recently updated and published in the January/February issue of CA: A Cancer Journal for Clinicians.